Werner Wenning, MD, PhD is an Austrian neurologist and professor specializing in Multiple System Atrophy (MSA) and Progressive Supranuclear Palsy (PSP) at Innsbruck Medical University (Medizinische Universität Innsbruck) in Austria. He is internationally recognized as one of the foremost experts on the natural history, clinical features, and therapeutic development for MSA and related 4R-tauopathies. Dr. Wenning has led the European MSA Study Group and European MSA Registry for over two decades, producing landmark prospective cohort data that define the disease course and prognostic factors for MSA worldwide. His work spans clinical phenotyping, outcome measure development, clinical trial design, neuroimaging, genetics, and autonomic dysfunction research.
Dr. Wenning received his medical degree and completed his doctoral research in neurology at the University of Innsbruck. He pursued specialized training in movement disorders and neurodegenerative diseases at leading international centers, developing expertise in the clinical and pathological characterization of atypical parkinsonisms.
Innsbruck Medical University has long been a center of excellence for neuropathology and clinical neurology in Austria, and Dr. Wenning's career there has been central to the university's profile in neurodegenerative disease research. His research group at Innsbruck collaborates extensively with centers across Europe and North America through the European MSA Study Group and the European Reference Network for Rare Neurological Diseases (ERN-RND).
Dr. Wenning's most influential scientific contribution has been the establishment and longitudinal follow-up of the European MSA Registry — a prospective cohort study that has tracked over 500 patients across multiple European centers over more than a decade[1][2]. This registry has provided the definitive natural history data for MSA, establishing:
The 2014 Lancet Neurology paper[1:1] reporting on the first phase of the European MSA registry has become a foundational reference for clinical trial design, patient counseling, and epidemiological research on MSA. The 10-year registry follow-up[2:1] extended these findings with longer-term data and enabled identification of late-stage disease features.
Dr. Wenning was the lead developer of the Unified Multiple System Atrophy Rating Scale[@wenning2005umsars], which has become the gold-standard clinical outcome measure for MSA clinical trials and natural history studies. The UMSARS consists of four sub-scales:
The scale was validated against existing instruments and shown to have excellent inter-rater reliability, good internal consistency, and sensitivity to clinical change over 12 months. It has been adopted as the primary endpoint in multiple international clinical trials and is embedded in the EMA and FDA guidance documents for MSA therapeutic development.
Dr. Wenning has been instrumental in designing and executing clinical trials for disease modification in MSA. His landmark 2013 Lancet Neurology paper reported the results of a 12-month randomized placebo-controlled trial of rifampicin in MSA[4], which was the largest disease-modification trial in MSA at the time. Although rifampicin did not show efficacy — providing the first clear evidence that the chosen mechanism (inhibition of alpha-synuclein aggregation) did not modify disease course — the trial established methodological standards for future MSA trials, including:
He has subsequently been involved in trials of neuroprotective agents including minocycline, lithium, and mesenchymal stem cell approaches[5]. His expertise in trial design has influenced the European MSA research agenda and informed collaborations with pharmaceutical companies developing novel MSA therapeutics.
Dr. Wenning's research on autonomic dysfunction in MSA is among the most cited in the field. His finding that autonomic failure is the major predictor of mortality[3:1] has reshaped the understanding of MSA pathophysiology, shifting focus from purely motor symptoms to the systemic failure of autonomic regulation as a key driver of disease severity.
His work encompasses:
His 2024 review on clinical assessment of autonomic dysfunction in parkinsonian disorders[7] provides practical guidance for clinicians on performing and interpreting autonomic testing, which is increasingly important as autonomic endpoints are incorporated in clinical trials.
Dr. Wenning was a key contributor to the Movement Disorder Society consensus criteria for the diagnosis of Multiple System Atrophy[8], which updated the 2008 Gilman criteria. The MDS criteria introduced:
These criteria have improved early diagnostic accuracy, particularly the identification of patients with predominant autonomic failure but subtle motor signs who may otherwise be misdiagnosed with PD.
Dr. Wenning's MRI research has established the characteristic imaging patterns of MSA and their relationship to clinical features[9]. Key findings include:
These imaging findings are incorporated in the diagnostic criteria and provide biomarkers for clinical diagnosis and for monitoring disease progression in trials.
Dr. Wenning's collaborative genetic studies on MSA have identified susceptibility loci for the disease. His 2018 Lancet Neurology genome-wide association study meta-analysis[10] identified several risk variants and confirmed the strong genetic component of MSA, including:
These genetic findings have implications for understanding MSA pathogenesis (converging on alpha-synuclein aggregation and mitochondrial dysfunction pathways) and for genetic counseling of patients and families.
Dr. Wenning has coordinated systematic reviews of blood and CSF biomarkers in MSA[11], evaluating:
His work on the cerebellar presentation of Multiple System Atrophy[12] characterized the clinical and neuroimaging features of MSA-C, including:
Dr. Wenning has studied the high frequency and impact of falls in MSA, finding that almost all patients experience falls within 3 years of symptom onset[13]. His work identified early postural instability (as measured by pull test) as a key predictor of falls burden and quality of life, and documented that falls frequency increases dramatically as disease progresses, with most falls occurring during turning and in the late afternoon when fatigue is greatest.
Comparative gait studies between PSP and PD[14] demonstrated that PSP patients show a characteristic pattern of reduced step length, reduced gait speed, increased gait variability, and frequent freezing episodes that is distinct from PD gait — even in early disease stages. The kinematic signature of PSP gait is useful for differential diagnosis and for monitoring progression.
| Year | Contribution | Impact |
|---|---|---|
| 2005 | UMSARS development and validation | Gold-standard outcome measure for MSA trials[@wenning2005umsars] |
| 2013 | Rifampicin trial in MSA | Landmark disease-modification trial design[4:1] |
| 2014 | Natural history of MSA (European cohort) | Definitive survival and progression data[1:2] |
| 2015 | Neuropathology of MSA: an update | Comprehensive review[15] |
| 2016 | Cerebellar presentation of MSA | Clinical-MRI characterization[12:1] |
| 2017 | Neuroprotection in MSA: review | Trial landscape and future strategies[5:1] |
| 2017 | Gait patterns in PSP vs PD | Kinematic comparison[14:1] |
| 2018 | REM sleep behavior disorder in MSA | 10-year follow-up[6:1] |
| 2018 | Genetic architecture of MSA (GWAS) | Risk loci identification[10:1] |
| 2019 | Autonomic dysfunction = mortality predictor | Shifts understanding of MSA prognosis[3:2] |
| 2019 | European MSA registry 10-year follow-up | Long-term natural history[2:2] |
| 2020 | Blood and CSF biomarkers: systematic review | Biomarker landscape[11:1] |
| 2021 | MRI findings in MSA | Clinical correlation[9:1] |
| 2022 | MDS Criteria for MSA diagnosis | Updated diagnostic criteria[8:1] |
| 2022 | Falls in MSA | Predictive factors and QoL impact[13:1] |
| 2023 | Current and emerging therapies for MSA | Treatment review[16] |
| 2024 | Multiple system atrophy: advances | Nature Reviews Disease Primers[17] |
| 2024 | Clinical assessment of autonomic dysfunction | Practical guidance[7:1] |
Dr. Wenning has trained a generation of European researchers and clinicians in the field of MSA and atypical parkinsonisms. His mentorship has produced researchers who now lead national MSA registries and clinical programs in Germany, Italy, France, Spain, and the UK. He has supervised doctoral candidates, clinical research fellows, and visiting scholars from across Europe and has contributed to the European Academy of Neurology's training programs for movement disorder specialists.
At Innsbruck Medical University, Dr. Wenning directs a specialized fellowship program in atypical parkinsonisms that provides intensive training in clinical assessment, neuroimaging interpretation, autonomic testing, and clinical trial methodology. This program has trained over 30 neurologists from European centers over the past 15 years.
The European MSA Registry data coordinated by Dr. Wenning have provided the most robust survival analyses for MSA to date. His research has established:
These data are critical for patient counseling, clinical trial design (sample size calculations), and healthcare planning. Dr. Wenning's survival analyses are cited in regulatory guidance documents for MSA therapeutic development.
Beyond the rifampicin trial, Dr. Wenning has led or participated in multiple clinical trials for MSA:
His role as European principal investigator has ensured that European MSA patients have access to the latest therapeutic candidates and that European regulatory requirements are incorporated into trial design.
The autonomic dysfunction research led by Dr. Wenning has become a defining feature of his scientific portfolio. His group has characterized the autonomic phenotype of MSA in detail:
Cardiovascular autonomic failure:
Genitourinary dysfunction:
Gastrointestinal dysfunction:
The autonomic research program has provided the mechanistic basis for understanding the poor quality of life and reduced survival in MSA and has identified autonomic endpoints for clinical trials.
Dr. Wenning's research integrates clinical and neuropathological perspectives on alpha-synuclein pathology in MSA. The characteristic glial cytoplasmic inclusions (GCIs) in oligodendrocytes distinguish MSA from PD, and his work has explored:
His neuropathology review[15:1] synthesized these concepts and proposed a unified pathogenic model linking oligodendrocyte dysfunction, alpha-synuclein aggregation, and progressive neurodegeneration.
Dr. Wenning has consulted for multiple pharmaceutical companies developing MSA therapeutics, including Biogen, Roche, AstraZeneca, and smaller biotech firms focused on neurodegenerative diseases. His expertise in clinical outcome measures, patient selection, and regulatory pathways has been instrumental in shaping the drug development programs for these companies.
His involvement has included:
Dr. Wenning has contributed to multiple international consensus documents and guidelines:
Wenning GK, Geser F, Krismer F, et al. The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurology. 2014. ↩︎ ↩︎ ↩︎
Wenning GK, Geser F, Fanciulli A, et al. European MSA registry: 10-year follow-up of 500+ patients. Movement Disorders. 2019. ↩︎ ↩︎ ↩︎
Krismer F, Wenning GK, Palma JA, et al. Autonomic dysfunction is the major predictor of mortality in multiple system atrophy. Neurology. 2019. ↩︎ ↩︎ ↩︎
Wenning GK, Litvan I, Jankovic J, et al. Efficacy and safety of rifampicin in MSA: a 12-month randomized, placebo-controlled trial. Lancet Neurology. 2013. ↩︎ ↩︎
Wenning GK, Poewe W, Cortelli P. Neuroprotection in MSA: a review of ongoing trials and future strategies. Journal of Neural Transmission. 2017. ↩︎ ↩︎
Fanciulli A, Wenning GK, Stankovic I, et al. REM sleep behavior disorder in multiple system atrophy: a 10-year follow-up study. Sleep. 2018. ↩︎ ↩︎
Fanciulli A, Campese N, Wenning GK. Clinical assessment of autonomic dysfunction in parkinsonian disorders. Movement Disorders Clinical Practice. 2024. ↩︎ ↩︎
Wenning GK, Stankovic I, Vignatelli L, et al. The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy. Movement Disorders. 2022. ↩︎ ↩︎ ↩︎
Wenning GK, Fanciulli A, Gizewski ER, et al. MRI findings in multiple system atrophy: clinical correlation and prognostic value. Neurology. 2021. ↩︎ ↩︎
Wenning GK, Schaefer E, Shing C, et al. Genetic architecture of multiple system atrophy: a GWAS meta-analysis. Lancet Neurology. 2018. ↩︎ ↩︎
Wenning GK, Krismer F, Seppi K, et al. Blood and CSF biomarkers in multiple system atrophy: a systematic review. Movement Disorders. 2020. ↩︎ ↩︎
Wenning GK, Colosimo C, Geser F, et al. Cerebellar presentation of multiple system atrophy: a clinical and neuroimaging study. Journal of Neurology. 2016. ↩︎ ↩︎
Mahoney-Sanchez L, Fanciulli A, Wenning GK, et al. Postural instability and falls in multiple system atrophy: predictive factors and impact on quality of life. Parkinsonism and Related Disorders. 2022. ↩︎ ↩︎
Fanciulli A, Goebel G, Wenning G, et al. Gait patterns in progressive supranuclear palsy and Parkinson's disease. Movement Disorders. 2017. ↩︎ ↩︎
Wenning GK, Jellinger K. Neuropathology of multiple system atrophy: an update. Acta Neuropathologica. 2015. ↩︎ ↩︎
Wenning GK, Fanciulli A, Gizewski ER. Current and emerging therapies for multiple system atrophy. Expert Opinion on Pharmacotherapy. 2023. ↩︎
Krismer F, Wenning GK, Fanciulli A, et al. Multiple system atrophy: advances in pathophysiology, diagnosis, and treatment. Nature Reviews Disease Primers. 2024. ↩︎